Descripción del proyecto
Un increíble dispositivo celular anuncia una revolución médica
Las células madre pluripotentes inducidas (CMPi o iPSC, por sus siglas en inglés) son capaces de madurar en cualquier célula humana que deseen y pueden trasplantarse sin ser rechazadas. Facilitan el desarrollo de una fuente ilimitada de cualquier tipo de célula humana necesaria para fines terapéuticos. Por ello, las CMPi resultan muy prometedoras para el tratamiento y la cura una amplia gama de problemas de salud. Sin embargo, los métodos existentes están frenando este enorme potencial. El objetivo del proyecto AiPSC, financiado por el Consejo Europeo de Innovación, es desarrollar un dispositivo microfluídico basado en inteligencia artificial, rentable, rápido y normalizado a fin de producir en masa CMPi personalizadas para inmunoterapias adoptivas contra el cáncer, trasplante de células madre hematopoyéticas y regeneración tisular. También se llevarán a cabo investigaciones de vanguardia en genómica unicelular y bioinformática sobre CMPi.
Objetivo
Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection. The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated disease and defective tissues, is unprecedented in history. However, the current methodologies prohibit standardized production of person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled. Our consortium seeks to develop a new technology that will enable the mass production of personalized iPSCs for autologous adoptive cancer immunotherapies, hematopoietic stem cell transplantation, and tissue regeneration.
The consortium will for the first time create an artificial intelligence (AI) guided microfluidic device that standardizes the GMP production of autologous iPSCs fast and at a fraction of the current cost. Moreover, it will conduct cutting-edge single cell genomics and bioinformatics research of iPSC to identify clones of highest quality, and develop a database that will be the basis for AI software to select clones that meet clinical standards. The consortium comprises of experts in microfluidics engineering process automation for cell therapies, stem cell molecular biology and bioinformatics, GMP production, and AI modelling. The participating companies, startups, and universities are amongst the leading in Europe, and will promote the positions of female and early career participants from developed and developing European countries. The consortium aims to reach TRL3 prototype stage, and have created a concrete exploitation plan to develop the technology further for implementation in cancer therapy and regenerative medicine. Altogether, we propose to create revolutionary technology for low cost, fast, and standardized automated mass production of autologous iPSCs, which holds the potential to enable numerous new therapies and making them accessible to the public.
Ámbito científico
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesclinical medicinetransplantation
Programa(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Tema(s)
Convocatoria de propuestas
HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-AG - HORIZON Action Grant Budget-BasedCoordinador
2333 CK LEIDEN
Países Bajos